{"DataElement":{"publicId":"7074831","version":"1","preferredName":"Best Overall Lesion Response CPTAC RECIST Type","preferredDefinition":"The CPTAC standard parameter used to document the response having the most positive qualities for a specific treatment regimen.","longName":"3861381v1.0:7074781v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"3861381","version":"1","preferredName":"Best Overall Lesion Response","preferredDefinition":"Having the most positive qualities._Including everything._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"3861379v1.0:2193203v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3861379","version":"1","preferredName":"Best Overall Lesion","preferredDefinition":"Having the most positive qualities.:Including everything.:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","longName":"C25432:C25605:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48AB905-C87B-6390-E040-BB89AD43301A","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2193203","version":"1","preferredName":"Response","preferredDefinition":"Response is any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","longName":"C25755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EACFDBFA-EFCE-25E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-09","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RECIST:Response Evaluation Criteria in Solid Tumors","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E48AB905-C889-6390-E040-BB89AD43301A","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-22","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":"8/31/17 tt transferred context, added registration status and CSI per Round 5 finalization task. 6/3/14 CDE/DEC released for DCP reuse. jc  8/22/13 created for RECIST CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7074781","version":"1","preferredName":"CPTAC RECIST Type","preferredDefinition":"The CPTAC standard parameters to be used when documenting response of solid tumors to treatment based on RECIST.","longName":"7074781v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"995DD1D4-BC3B-29EE-E053-F662850A3248","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","deletedIndicator":"No"},{"value":"Progressive Disease","valueDescription":"RECIST Progressive Disease","ValueMeaning":{"publicId":"7074783","version":"1","preferredName":"RECIST Progressive Disease","longName":"7074783","preferredDefinition":"At lease a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIST Progressive Disease","conceptCode":"C159716","definition":"At lease a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DD1D4-BC49-29EE-E053-F662850A3248","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"995DD1D4-BC62-29EE-E053-F662850A3248","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","deletedIndicator":"No"},{"value":"Complete Response","valueDescription":"RECIST Complete Response","ValueMeaning":{"publicId":"7074785","version":"1","preferredName":"RECIST Complete Response","longName":"7074785","preferredDefinition":"Disappearance of all target lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIST Complete Response","conceptCode":"C159715","definition":"Disappearance of all target lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DD1D4-BC6F-29EE-E053-F662850A3248","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"SOKKERL","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"995DD1D4-BC88-29EE-E053-F662850A3248","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","deletedIndicator":"No"},{"value":"Partial Response","valueDescription":"RECIST Partial Response","ValueMeaning":{"publicId":"7074787","version":"1","preferredName":"RECIST Partial Response","longName":"7074787","preferredDefinition":"At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIST Partial Response","conceptCode":"C159547","definition":"At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DD1D4-BC95-29EE-E053-F662850A3248","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"SOKKERL","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"995DD1D4-BCAE-29EE-E053-F662850A3248","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","deletedIndicator":"No"},{"value":"Stable Disease","valueDescription":"RECIST Stable Disease","ValueMeaning":{"publicId":"7074789","version":"1","preferredName":"RECIST Stable Disease","longName":"7074789","preferredDefinition":"Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIST Stable Disease","conceptCode":"C159546","definition":"Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DD1D4-BCBB-29EE-E053-F662850A3248","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"995DD1D4-BCD4-29EE-E053-F662850A3248","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7074780","version":"1","preferredName":"Clinical Proteomic Tumor Analysis Consortium Response Evaluation Criteria in Solid Tumors Type","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com):Something distinguishable as an identifiable class based on common qualities.","longName":"C157175:C49164:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response Evaluation Criteria in Solid Tumors","conceptCode":"C49164","definition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DD1D4-BC13-29EE-E053-F662850A3248","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"ONEDATA","dateModified":"2019-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DD1D4-BC24-29EE-E053-F662850A3248","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"KNABLEJ","dateModified":"2020-02-20","changeDescription":"2/20/20 jk CPTAC/Linda approved CDE; CDE released, RS kept Application. 12/10/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776734","version":"1","longName":"All Generic CRFs","context":"OCCPR"},{"publicId":"6601274","version":"1","longName":"Follow Up","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Best Overall Response (RECIST)","type":"Preferred Question Text","description":"Best Overall Response (RECIST)","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"995DF9C5-3CAC-4C51-E053-F662850A078C","latestVersionIndicator":"Yes","beginDate":"2019-12-10","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-10","modifiedBy":"KNABLEJ","dateModified":"2020-02-20","changeDescription":"2/20/20 jk CPTAC/Linda approved CDE; CDE released, RS kept Application. 12/10/19 jk created for CPTAC follow up CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}